These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36210241)

  • 1. Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
    Lu LC; Chao CM; Chang SP; Lan SH; Lai CC
    Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1471-1478. PubMed ID: 36210241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.
    Saeki H; Ito K; Yokota D; Tsubouchi H
    J Am Acad Dermatol; 2022 Mar; 86(3):607-614. PubMed ID: 34710557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.
    Saeki H; Baba N; Ito K; Yokota D; Tsubouchi H
    Br J Dermatol; 2022 Jan; 186(1):40-49. PubMed ID: 34289086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
    Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
    J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study.
    Saeki H; Imamura T; Yokota D; Tsubouchi H
    Dermatol Ther (Heidelb); 2022 Jul; 12(7):1589-1601. PubMed ID: 35716332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
    JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    Ma L; Zhang L; Kobayashi M; Tao X; Qian Q; Cheng H; Liu S; Zhou Y; Chen Y; Zhang J
    J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.
    Saeki H; Ohya Y; Baba N; Imamura T; Yokota D; Tsubouchi H
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2443-2455. PubMed ID: 39075274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
    Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
    Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
    Chu DK; Chu AWL; Rayner DG; Guyatt GH; Yepes-Nuñez JJ; Gomez-Escobar L; Pérez-Herrera LC; Díaz Martinez JP; Brignardello-Petersen R; Sadeghirad B; Wong MM; Ceccacci R; Zhao IX; Basmaji J; MacDonald M; Chu X; Islam N; Gao Y; Izcovich A; Asiniwasis RN; Boguniewicz M; De Benedetto A; Capozza K; Chen L; Ellison K; Frazier WT; Greenhawt M; Huynh J; LeBovidge J; Lio PA; Martin SA; O'Brien M; Ong PY; Silverberg JI; Spergel JM; Smith Begolka W; Wang J; Wheeler KE; Gardner DD; Schneider L
    J Allergy Clin Immunol; 2023 Dec; 152(6):1493-1519. PubMed ID: 37678572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao DJ; Huang LM; Xiao J; Chen L; Li X; Lin HX
    Medicine (Baltimore); 2023 Aug; 102(31):e34516. PubMed ID: 37543792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
    Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
    J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of clinician-assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta-analysis.
    Légaré S; Chagnon M; Palijan A; Kojok K; Bissonnette R
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):196-212. PubMed ID: 34661930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
    Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
    J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difamilast for the treatment of atopic dermatitis.
    Freitas E; Torres T
    J Int Med Res; 2023 Jun; 51(6):3000605231169445. PubMed ID: 37389929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
    Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
    Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
    Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
    Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.